Centers | ||
|
|
|
Edinburgh Drug Discovery | Chemical Genomics Facility at Purdue Institute for Drug Discovery | Therapeutic Accelerator Program (TAP) |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
The Chemical Genomics Facility is a core facility at Purdue Institute for Drug Discovery that provides expertise and resources needed in the early stage of drug discovery. The services include small molecule libraries, access to automated equipment... Read more |
Test |
Partnerships |
Events |
Jobs |
Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all Johnson & Johnson to Support Pain Research at Queensland UniversityJohnson & Johnson and Institute for Molecular Bioscience (IMB) at University of Queensland have entered into research agreement to develop peptides using IMB's novel assay to treat chronic pain. Johnson & Johnson and its affiliates will provide... View all Vanderbilt and Astra Zeneca to Develop New Drugs to Treat Psychosis and Other Brain DisordersUnder a new research collaboration agreement, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Astra Zeneca will work together to develop compounds that act on M4 muscarinic acetylcholine receptor. The agreement entails research... View all |
No EVENTS for listing |
No Job Posts |
